Brightpath Biotherapeutics Co. Ltd. filed an Investigational New Drug (IND) application with the FDA to start a phase I trial of BP-2202 in the U.S., according to an update referencing NCT07667868. The move opens a clinical path for early safety and tolerability data as the company advances its oncology pipeline.